肿瘤细胞治疗研究
英文原题：Primary CNS lymphoma: update on molecular pathogenesis and therapy.
Primary CNS lymphoma: update on molecular pathogenesis and therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
原发性中枢神经系统淋巴瘤（PCNSL）是一种罕见且侵袭性的结外非霍奇金淋巴瘤，作为脑肿瘤在诊断和管理方面带来了一系列独特的挑战。
原发性中枢神经系统淋巴瘤（PCNSL）是一种罕见且侵袭性强的非霍奇金淋巴瘤结外亚型；作为脑肿瘤，它在诊断和管理方面面临独特挑战。随着新一代测序技术出现，本文综述对其分子和基因组发病机制的新认识，并重点介绍管理中的关键问题，关注新兴技术和新型生物疗法，包括单克隆抗体、免疫调节药物（IMiD）、布鲁顿酪氨酸激酶（BTK）抑制剂、PD-1抑制剂和CAR-T 治疗。整合应用这些方法可能增强诱导和巩固治疗效果，抑制NF-κB活化及抗肿瘤免疫应答，同时尽量减少基因毒性治疗常见的有害作用。
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive form of extra-nodal non-Hodgkin lymphoma that as a brain tumor poses a unique set of challenges in diagnosis and management. With the advent of next-generation sequencing, we review updates in the understanding of its molecular and genomic pathogenesis. We also highlight key issues in management, with a focus on emerging technologies and new biological therapies including monoclonal antibodies, IMiDs, BTK inhibitors, PD-1 inhibitors, and CAR-T therapy. Integration of these approaches will likely enhance induction and consolidation strategies to suppress NF- B activation and the anti-tumor immune response, while minimizing the often noxious effects of genotoxic approaches.
MEMBER ACCOUNT
登录成功会直接打开下一页。
